文献速递心境障碍

系列氯胺酮输注治疗难治性双相抑郁:一项随机临床试验

Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2026-09-02

该双盲、米达唑仑对照随机临床试验在加拿大安大略省3个中心纳入68例难治性双相I或II型抑郁成人门诊患者,比较辅助静脉氯胺酮与米达唑仑的疗效与安全性。

要点

  • 辅助静脉氯胺酮治疗难治性双相抑郁在第14天MADRS评分显著优于米达唑仑。
  • 研究中未观察到躁狂、轻躁狂、精神病或自杀未遂,每组各1例阈下混合特征。
  • 首次输注后47%(31/66)参与者能正确猜测治疗分配,提示盲法可能受影响。

核心结论

  • 在难治性双相I或II型抑郁中,辅助静脉氯胺酮耐受良好,与米达唑仑相比具有显著抗抑郁效应。

研究设计与样本

  • 研究者发起的双盲、米达唑仑对照随机临床试验,在加拿大安大略省3个中心开展,时间为2022年7月至2025年11月。
  • 纳入21-65岁成人门诊患者,DSM-5双相I或II型障碍,当前中重度抑郁发作(MADRS≥21),且至少2种循证药物治疗失败。
  • 参与者按1:1随机接受2周内4次40分钟灵活剂量输注,氯胺酮0.5-0.75 mg/kg或米达唑仑0.02-0.03 mg/kg,辅助稳定剂量的至少1种心境稳定剂或抗精神病药。
  • 共68例随机(平均年龄44.4岁,SD 11.8;女性38例,55.8%),63例纳入最终疗效分析,5例在主要终点前退出(氯胺酮1例,米达唑仑4例)。

主要发现

  • 两组均未观察到躁狂、轻躁狂、精神病或自杀未遂;每组各观察到1例混合特征(阈下轻躁狂症状)。
  • 首次输注后,66例参与者中31例(47%)正确猜测治疗分配。

关键数值与推荐

  • 主要终点为基线至治疗结束(第14天)观察者评定MADRS评分变化。
  • 安全性评估包括密切监测治疗中出现的躁狂、轻躁狂、混合特征或精神病。

临床怎么用

  • 对于至少2种循证药物治疗失败的难治性双相抑郁成人患者,辅助静脉氯胺酮可能改善抑郁症状严重度。
  • 使用氯胺酮时需密切监测躁狂、轻躁狂、混合特征和精神病性症状,尽管本试验未观察到这些事件。
  • 首次输注后近半数参与者能猜出治疗分配,临床解读疗效时需考虑盲法可能受损的影响。

局限性

  • 样本量较小,最终疗效分析仅63例。
  • 首次输注后47%参与者正确猜测治疗分配,提示盲法可能受影响。
  • 研究在加拿大3个中心开展,外推性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Antidepressant efficacy of intravenous (IV) ketamine has been demonstrated in major depressive disorder; however, the efficacy and safety of ketamine for bipolar depression remain largely unknown, with limited data available in this specific population. OBJECTIVE: To evaluate the efficacy, safety, and tolerability of adjunctive IV ketamine compared with midazolam for treatment-resistant bipolar I or II depression (TRBD). DESIGN, SETTING, AND PARTICIPANTS: The Ket-BD study (Ketamine for Treatment-Resistant Bipolar Disorder) was an investigator-led, double-blind, midazolam-controlled randomized clinical trial conducted at 3 sites in Ontario, Canada, from July 2022 to November 2025. Participants included adult outpatients (aged 21-65 years) with a primary bipolar I or II disorder DSM-5 diagnosis with a current moderate to severe major depressive episode (Montgomery-Åsberg Depression Rating Scale [MADRS] score ≥21), having had at least 2 failed trials of evidence-based pharmacotherapies. Data were analyzed from November 2025 through February 2026. INTERVENTIONS: Participants were randomized 1:1 to receive 4 flexibly dosed 40-minute infusions over 2 weeks of either ketamine (0.5-0.75 mg/kg) or midazolam (0.02-0.03 mg/kg) adjunctive to a stable dose of at least 1 mood stabilizer or antipsychotic. MAIN OUTCOMES AND MEASURES: The primary outcome was change in depression symptom severity measured by the observer-rated MADRS score from baseline to end of treatment (day 14). Safety and tolerability were assessed with close evaluation for potential treatment-emergent mania, hypomania, mixed features, or psychosis. RESULTS: Of 68 randomized participants (mean [SD] age, 44.4 [11.8] years; 38 female [55.8%]), 63 were included in the final efficacy analysis as 5 participants withdrew (1 ketamine, 4 midazolam) before the primary end point. In the primary efficacy analysis, controlling for sex, bipolar type, and baseline MADRS, the mean MADRS score at day 14 was significantly lower in the ketamine group compared to the midazolam group (between-group difference = -7.3 points; 95% CI, -12.0 to -2.5; P = .003; Cohen d = 0.7). No cases of mania, hypomania, psychosis, or suicide attempts were observed in either group. One case of mixed features (subthreshold hypomanic symptoms) was observed in each group. After the first infusion, 31 of 66 participants (47%) correctly guessed treatment allocation. CONCLUSIONS AND RELEVANCE: In TRBD, adjunctive IV ketamine was well tolerated and associated with significant antidepressant effects compared to midazolam. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05004896.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Orsini DK, Di Luch S, Tomlinson G, et al. Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2026. PMID: 42684694. doi:10.1001/jamapsychiatry.2026.2658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。